MA53145A - Agents de liaison cd123 et leurs utilisations - Google Patents
Agents de liaison cd123 et leurs utilisationsInfo
- Publication number
- MA53145A MA53145A MA053145A MA53145A MA53145A MA 53145 A MA53145 A MA 53145A MA 053145 A MA053145 A MA 053145A MA 53145 A MA53145 A MA 53145A MA 53145 A MA53145 A MA 53145A
- Authority
- MA
- Morocco
- Prior art keywords
- liaison
- agents
- liaison agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046682P | 2014-09-05 | 2014-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53145A true MA53145A (fr) | 2021-05-19 |
Family
ID=54150667
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053145A MA53145A (fr) | 2014-09-05 | 2015-09-03 | Agents de liaison cd123 et leurs utilisations |
| MA40609A MA40609B1 (fr) | 2014-09-05 | 2015-09-03 | Agents de liaison cd123 et leurs utilisations |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40609A MA40609B1 (fr) | 2014-09-05 | 2015-09-03 | Agents de liaison cd123 et leurs utilisations |
Country Status (39)
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068268T2 (hu) | 2010-04-20 | 2024-12-28 | Genmab As | Heterodimer antitest Fc-t tartalmazó fehérjék és azok elõállítási eljárásai |
| TN2017000275A1 (en) | 2015-01-23 | 2018-10-19 | Sanofi Sa | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| US10100118B2 (en) | 2015-04-08 | 2018-10-16 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD123 |
| KR101997241B1 (ko) | 2015-05-21 | 2019-07-09 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| BR112017027254A2 (pt) | 2015-06-29 | 2019-05-14 | Immunogen, Inc. | anticorpos anti-cd123 e conjugados e derivados dos mesmos |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| SG11201804839WA (en) | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| CN109641046B (zh) * | 2016-05-20 | 2023-11-07 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CA3025995C (en) * | 2016-06-06 | 2023-08-08 | F. Hoffmann-La Roche Ag | Fusion proteins for ophthalmology with increased eye retention |
| EP3463464A4 (en) | 2016-06-07 | 2020-07-01 | MacroGenics, Inc. | ASSOCIATION TREATMENT |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| CN107840889A (zh) * | 2016-09-19 | 2018-03-27 | 上海吉倍生物技术有限公司 | 高亲和力的抗cd123抗体及其应用 |
| EP3515491A4 (en) * | 2016-09-21 | 2020-09-16 | Aptevo Research and Development LLC | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES |
| BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
| US10849973B2 (en) | 2016-11-23 | 2020-12-01 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
| WO2018102795A2 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| JP7231549B2 (ja) * | 2017-02-06 | 2023-03-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| KR102585848B1 (ko) | 2017-02-24 | 2023-10-11 | 마크로제닉스, 인크. | Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도 |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| WO2018166461A1 (en) * | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| WO2018209304A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| WO2019034580A1 (en) | 2017-08-14 | 2019-02-21 | Morphosys Ag | HUMANIZED ANTIBODIES FOR CD3 |
| WO2019050521A1 (en) * | 2017-09-07 | 2019-03-14 | Macrogenics, Inc. | DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| WO2019075359A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS AND METHODS OF USE |
| CA3205442A1 (en) * | 2017-10-27 | 2019-05-02 | Pfizer, Inc. | Antibodies and antibody-drug conjugates specific for cd123 and uses thereof |
| SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| MX2020008489A (es) | 2018-02-15 | 2020-09-25 | Macrogenics Inc | Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades. |
| WO2019175658A1 (en) * | 2018-03-14 | 2019-09-19 | Novimmune Sa | Anti-cd3 epsilon antibodies and methods of use thereof |
| US12415860B2 (en) | 2018-05-14 | 2025-09-16 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| MX2020012286A (es) | 2018-05-16 | 2021-04-28 | Janssen Biotech Inc | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t. |
| MX2020012589A (es) | 2018-05-24 | 2021-01-29 | Janssen Biotech Inc | Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos. |
| SG11202011633SA (en) | 2018-05-24 | 2020-12-30 | Janssen Biotech Inc | Psma binding agents and uses thereof |
| JOP20190116A1 (ar) * | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| BR112021005769A2 (pt) | 2018-09-25 | 2021-07-06 | Harpoon Therapeutics Inc | proteínas de ligação a dll3 e métodos de uso |
| CN113056485A (zh) * | 2018-10-17 | 2021-06-29 | 古德T细胞有限公司 | Lrig-1蛋白的特异性结合分子及其用途 |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| CN113874400B (zh) * | 2019-03-11 | 2025-02-07 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| BR112021020532A2 (pt) | 2019-04-19 | 2022-03-15 | Janssen Biotech Inc | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 |
| CR20210548A (es) * | 2019-05-08 | 2022-02-11 | Janssen Biotech Inc | Materiales y métodos para modular la inmunidad mediada por células t |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| CN113912695B (zh) * | 2019-07-24 | 2023-05-30 | 暨南大学 | 靶向cd133的结合蛋白及应用 |
| GB201912681D0 (en) | 2019-09-04 | 2019-10-16 | Eth Zuerich | Bispecific binding agent that binds to cd117/c-kit and cd3 |
| MX2022010228A (es) | 2020-02-21 | 2022-09-19 | Macrogenics Inc | Moleculas de union a cd137 y usos de las mismas. |
| BR112022016550A2 (pt) | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
| TW202144418A (zh) | 2020-03-13 | 2021-12-01 | 美商健生生物科技公司 | 唾液酸結合Ｉｇ樣凝集素結合的材料及方法 |
| CA3183905A1 (en) * | 2020-05-19 | 2021-11-25 | Janssen Biotech, Inc | Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor |
| CA3183325A1 (en) | 2020-05-19 | 2021-11-25 | The Regents Of The University Of California | Conjugate polypeptides and vaccines for inducing immune responses |
| AU2021364387A1 (en) * | 2020-10-23 | 2023-06-15 | Asher Biotherapeutics, Inc. | Fusions with cd8 antigen binding molecules for modulating immune cell function |
| JP7623497B2 (ja) | 2020-12-31 | 2025-01-28 | サノフイ | ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ |
| US12274747B2 (en) | 2021-01-28 | 2025-04-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| AU2022278013A1 (en) | 2021-05-18 | 2024-01-18 | Janssen Biotech, Inc. | Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic |
| CA3219181A1 (en) | 2021-05-19 | 2022-11-24 | Yik Andy Yeung | Il-21 polypeptides and targeted constructs |
| JP2024531149A (ja) * | 2021-08-09 | 2024-08-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 炎症誘発性サイトカイン放出からｔ細胞性腫瘍細胞毒性をデカップリングするタンパク質 |
| US20250144213A1 (en) * | 2022-01-19 | 2025-05-08 | Utc Therapeutics (Shanghai) Co., Ltd. | Circular rna and use thereof |
| CA3247475A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharma | COMPOSITIONS AND METHODS FOR THE DESTRUCTION OF UNIVERSAL TUMOR CELLS |
| TW202413419A (zh) | 2022-05-27 | 2024-04-01 | 法商賽諾菲公司 | 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物 |
| KR20250151441A (ko) | 2023-02-17 | 2025-10-21 | 리제너론 파마슈티칼스 인코포레이티드 | Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
| ES2243007T3 (es) | 1997-09-16 | 2005-11-16 | Egea Biosciences Llc | Sintesis quimica completa y sintesis de genes de genomas. |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| BRPI0619056A2 (pt) | 2005-11-28 | 2011-09-20 | Genmab As | anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| WO2010126066A1 (ja) * | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗IL-3Rα抗体 |
| AU2010245011B2 (en) | 2009-04-27 | 2015-09-03 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| CA2772945A1 (en) * | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Screening methods |
| HUE068268T2 (hu) | 2010-04-20 | 2024-12-28 | Genmab As | Heterodimer antitest Fc-t tartalmazó fehérjék és azok elõállítási eljárásai |
| NZ604510A (en) * | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス，インコーポレイテッド | Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
| DK2773671T3 (da) | 2011-11-04 | 2021-11-15 | Zymeworks Inc | Udformning af stabilt heterodimert antistof med mutationer i fc-domænet |
| EP4053162A1 (en) * | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
-
2015
- 2015-09-03 HR HRP20200745TT patent/HRP20200745T1/hr unknown
- 2015-09-03 SI SI201531192T patent/SI3189081T1/sl unknown
- 2015-09-03 SM SM20200253T patent/SMT202000253T1/it unknown
- 2015-09-03 LT LTEP15766973.0T patent/LT3189081T/lt unknown
- 2015-09-03 US US14/844,194 patent/US9850310B2/en active Active
- 2015-09-03 EP EP20157898.6A patent/EP3722315A1/en not_active Withdrawn
- 2015-09-03 HU HUE15766973A patent/HUE048791T2/hu unknown
- 2015-09-03 DK DK15766973.0T patent/DK3189081T3/da active
- 2015-09-03 RS RS20200573A patent/RS60305B1/sr unknown
- 2015-09-03 MA MA053145A patent/MA53145A/fr unknown
- 2015-09-03 PT PT157669730T patent/PT3189081T/pt unknown
- 2015-09-03 ES ES15766973T patent/ES2791249T3/es active Active
- 2015-09-03 TW TW104129109A patent/TWI693233B/zh not_active IP Right Cessation
- 2015-09-03 UA UAA201703200A patent/UA120060C2/uk unknown
- 2015-09-03 AU AU2015311931A patent/AU2015311931B2/en not_active Ceased
- 2015-09-03 WO PCT/US2015/048316 patent/WO2016036937A1/en not_active Ceased
- 2015-09-03 CN CN201580060369.4A patent/CN107074956B/zh active Active
- 2015-09-03 MY MYPI2017700741A patent/MY186337A/en unknown
- 2015-09-03 KR KR1020177008815A patent/KR102540192B1/ko active Active
- 2015-09-03 JO JOP/2015/0216A patent/JO3568B1/ar active
- 2015-09-03 ME MEP-2020-93A patent/ME03724B/me unknown
- 2015-09-03 MA MA40609A patent/MA40609B1/fr unknown
- 2015-09-03 EA EA201790530A patent/EA037647B1/ru unknown
- 2015-09-03 MX MX2017002891A patent/MX384424B/es unknown
- 2015-09-03 PE PE2017000397A patent/PE20171556A1/es unknown
- 2015-09-03 PL PL15766973T patent/PL3189081T3/pl unknown
- 2015-09-03 SG SG11201701599UA patent/SG11201701599UA/en unknown
- 2015-09-03 JP JP2017512813A patent/JP6805130B2/ja active Active
- 2015-09-03 EP EP15766973.0A patent/EP3189081B1/en active Active
- 2015-09-03 CR CR20170079A patent/CR20170079A/es unknown
- 2015-09-03 CA CA2959171A patent/CA2959171C/en active Active
- 2015-09-04 AR ARP150102836A patent/AR101765A1/es unknown
- 2015-09-04 UY UY0001036289A patent/UY36289A/es not_active Application Discontinuation
-
2017
- 2017-02-26 IL IL250770A patent/IL250770B/en active IP Right Grant
- 2017-03-03 NI NI201700025A patent/NI201700025A/es unknown
- 2017-03-03 CL CL2017000515A patent/CL2017000515A1/es unknown
- 2017-03-06 CO CONC2017/0002196A patent/CO2017002196A2/es unknown
- 2017-03-13 PH PH12017500472A patent/PH12017500472A1/en unknown
- 2017-04-04 ZA ZA2017/02369A patent/ZA201702369B/en unknown
- 2017-04-05 EC ECIEPI201720812A patent/ECSP17020812A/es unknown
-
2020
- 2020-05-18 CY CY20201100453T patent/CY1122858T1/el unknown
- 2020-12-02 JP JP2020199977A patent/JP2021050216A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
| FIC20230014I1 (fi) | Foslevodopa ja foskarbidopa | |
| EP3334706A4 (en) | PILLARARES AND USES THEREOF | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3344275A4 (en) | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | |
| MA40933A (fr) | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines | |
| EP3313530A4 (en) | 4,6-PYRIMIDINYLENE DERIVATIVES AND USE THEREOF | |
| EP3337486A4 (en) | DEUTERIZED CONNECTIONS AND USES THEREOF | |
| EP3294318A4 (en) | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | |
| EP3334572A4 (en) | EXOANZUG | |
| BR112017019682A2 (pt) | fluoropolímeros modificados | |
| EP3341387A4 (en) | SIALYL TRANSFERASE INHIBITORS AND USES THEREOF | |
| EP3333833A4 (en) | TECHNOLOGY SIMULATOR | |
| EP3538261A4 (en) | Perovskite catalysts and uses thereof | |
| EP3347021A4 (en) | CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF | |
| EP3302490A4 (en) | AUTOTAXIN INHIBITORS AND USES THEREOF | |
| EP3347020A4 (en) | ACETAMIDE-THIENOTRIAZOLDIAZEPINE AND USES THEREOF | |
| MA46901A (fr) | Agents psychotropes et leurs utilisations | |
| EP3450444A4 (en) | CROCINE COMPOUNDS AND USES THEREOF | |
| MA41022A (fr) | Ciblage lysosomial et utilisations correspondantes | |
| EP3377897A4 (en) | LACTATE BIO SENSORS AND USES THEREOF | |
| EP3370771A4 (en) | ANTI-CD3-FOLAT-CONJUGATES AND ITS USES | |
| EP3405044A4 (en) | BIOKONSERVATION COMPOSITION FOR FOODSTUFFS AND USES THEREOF | |
| MA46945A (fr) | Exopolysaccharides et leurs utilisations |